Sollpura

Novel, biotechnology-derived pancreatic enzyme replacement therapy for the potential treatment of exocrine pancreatic insufficiency due to cystic fibrosis and other conditions.

Learn more about Sollpura

Blisibimod

B-cell activating factor (BAFF) inhibitor for the potential treatment of IgA nephropathy.

Learn more about Blisibimod

LATEST NEWS

Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal.

READ MORE

Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 Clinical Study of Sollpura.

READ MORE